JP2022536929A5 - - Google Patents
Info
- Publication number
- JP2022536929A5 JP2022536929A5 JP2021574188A JP2021574188A JP2022536929A5 JP 2022536929 A5 JP2022536929 A5 JP 2022536929A5 JP 2021574188 A JP2021574188 A JP 2021574188A JP 2021574188 A JP2021574188 A JP 2021574188A JP 2022536929 A5 JP2022536929 A5 JP 2022536929A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- transgene
- adenovirus vector
- oncolytic adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101398A JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861339P | 2019-06-14 | 2019-06-14 | |
| US62/861,339 | 2019-06-14 | ||
| US202062988422P | 2020-03-12 | 2020-03-12 | |
| US62/988,422 | 2020-03-12 | ||
| PCT/FI2020/050422 WO2020249873A1 (en) | 2019-06-14 | 2020-06-12 | Oncolytic adenovirus and checkpoint inhibitor combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101398A Division JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536929A JP2022536929A (ja) | 2022-08-22 |
| JP2022536929A5 true JP2022536929A5 (https=) | 2023-06-20 |
Family
ID=71670283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574188A Pending JP2022536929A (ja) | 2019-06-14 | 2020-06-12 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
| JP2025101398A Pending JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101398A Pending JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220251604A1 (https=) |
| EP (1) | EP3983004A1 (https=) |
| JP (2) | JP2022536929A (https=) |
| KR (1) | KR20220024495A (https=) |
| CN (1) | CN113924117A (https=) |
| AU (1) | AU2020292610A1 (https=) |
| BR (1) | BR112021025031A2 (https=) |
| CA (1) | CA3138834A1 (https=) |
| SG (1) | SG11202111820PA (https=) |
| WO (1) | WO2020249873A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022170919A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京惟亚德生物医药有限公司 | 一种重组溶瘤腺病毒及其应用 |
| CN118055776A (zh) | 2021-10-04 | 2024-05-17 | 蒂尔坦生物制药有限公司 | 编码白细胞介素-7(il-7)多肽的溶瘤病毒载体 |
| KR20250158053A (ko) * | 2023-03-01 | 2025-11-05 | 틸트 바이오세러퓨틱스 오이 | 종양용해성 아데노바이러스 벡터의 새로운 투여 요법 |
| WO2024207425A1 (en) * | 2023-04-07 | 2024-10-10 | Virogin Biotech (Shanghai) Ltd. | Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer |
| CN120835927A (zh) * | 2023-09-28 | 2025-10-24 | 复旦大学附属华山医院 | 用于治疗胶质瘤的组合物 |
| JP7816735B2 (ja) * | 2024-01-22 | 2026-02-18 | 国立大学法人 鹿児島大学 | 腫瘍溶解性ウイルス及びそれを用いたがん治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| DK2986311T3 (en) | 2013-04-18 | 2019-02-25 | Tilt Biotherapeutics Oy | IMPROVED ADOPTIVE CELL THERAPY |
-
2020
- 2020-06-12 US US17/618,932 patent/US20220251604A1/en active Pending
- 2020-06-12 CN CN202080039001.0A patent/CN113924117A/zh active Pending
- 2020-06-12 BR BR112021025031A patent/BR112021025031A2/pt unknown
- 2020-06-12 SG SG11202111820PA patent/SG11202111820PA/en unknown
- 2020-06-12 JP JP2021574188A patent/JP2022536929A/ja active Pending
- 2020-06-12 CA CA3138834A patent/CA3138834A1/en active Pending
- 2020-06-12 EP EP20742793.1A patent/EP3983004A1/en active Pending
- 2020-06-12 KR KR1020227000995A patent/KR20220024495A/ko active Pending
- 2020-06-12 WO PCT/FI2020/050422 patent/WO2020249873A1/en not_active Ceased
- 2020-06-12 AU AU2020292610A patent/AU2020292610A1/en active Pending
-
2025
- 2025-06-17 JP JP2025101398A patent/JP2025138703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536929A5 (https=) | ||
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| Howells et al. | Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer | |
| JP2025100670A5 (https=) | ||
| US20180369304A1 (en) | Virus encoding an anti-tcr-complex antibody or fragment | |
| JP2020521471A (ja) | 導入遺伝子を保持する組換えアデノウイルス | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| JP2021533789A5 (https=) | ||
| US11690913B2 (en) | Combining adenovirus and checkpoint inhibitors for treating cancer | |
| JP2018509914A (ja) | 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用 | |
| CN105307671A (zh) | 增强过继细胞疗法 | |
| JP2020504767A (ja) | 武装した複製可能な腫瘍溶解性アデノウイルス | |
| Huang et al. | Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses | |
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| Corti et al. | Novel immune targets for the treatment of triple-negative breast cancer | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| Wei et al. | Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice | |
| Sultan et al. | Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment | |
| JP7381604B2 (ja) | 癌を治療するための多価ｐｄ－ｌ１結合化合物 | |
| JP2024038026A (ja) | 活性成分として抗がんウイルス、免疫チェックポイント阻害剤及びヒドロキシ尿素を含む、がんを処置するための医薬組成物 | |
| Zhu et al. | Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors | |
| Li et al. | Oncolytic viruses in cancer immunotherapy | |
| Wang et al. | Novel combination oncolytic adenoviral gene therapy armed with Dm-dNK and CD40L for breast cancer | |
| JP2022502066A (ja) | 癌治療のための修飾ｂ５ｒ遺伝子を有する腫瘍溶解性ワクシニアウイルス | |
| JP7699122B2 (ja) | 複製促進腫瘍溶解性アデノウイルス |